Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Detalles Bibliográficos
Autor principal: Saba, Nabil F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346538/
https://www.ncbi.nlm.nih.gov/pubmed/28348975
http://dx.doi.org/10.3389/fonc.2017.00031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346538/
https://www.ncbi.nlm.nih.gov/pubmed/28348975
http://dx.doi.org/10.3389/fonc.2017.00031

Ejemplares similares